Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Feb;102(2):446–452. doi: 10.1111/j.1476-5381.1991.tb12193.x

Very high affinity interaction of DPI 201-106 and BDF 8784 enantiomers with the phenylalkylamine-sensitive Ca2(+)-channel in Drosophila head membranes.

H Glossmann 1, C Zech 1, J Striessnig 1, R Staudinger 1, L Hall 1, R Greenberg 1, B I Armah 1
PMCID: PMC1918021  PMID: 1849770

Abstract

1. Piperazinylindoles (DPI 201-106, BDF 8784), drugs known to act on voltage-dependent Na(+)-channels, bind with very high affinity to a Ca2(+)-channel-associated phenylalkylamine receptor in Drosophila melanogaster head membranes. These compounds and (+)-tetrandrine, a naturally occurring Ca2(+)-antagonist, were the most selective inhibitors for phenylalkylamine-labelled Drosophila Ca2(+)-channels compared to mammalian L-type Ca2(+)-channels. 2. Replacement of the cyano group by a methyl group in (+)-DPI 201-106 ((+)-BDF 8784) increases the IC50 value for inhibition of phenylalkylamine labelling of Drosophila Ca2(+)-channels from 0.29 to 2.1 nM but decreases the IC50 value for inhibition of phenylalkylamine labelling of mammalian skeletal muscle Ca2(+)-channels from 3480 to 49 nM. 3. DPI 201-106 enantiomers completely block (at 0.1 microM) phenylalkylamine photolabelling of a 136 K polypeptide in Drosophila head membranes whereas 10 microM aconitine or lidocaine are without effect. 4. Assessment of the Ca2(+)-antagonist effects of the substituted DPI 201-106 enantiomers in K(+)-depolarized taenia strips from guinea-pig caecum yielded pA2 values of 6.33 +/- 0.07 for (-)-BDF 8784 and 6.99 +/- 0.17 for (+)-BDF 8784, respectively. 5. Piperazinylindoles, previously believed to act nonspecifically on voltage-dependent mammalian L-type Ca2(+)-channels, therefore have stereoselectivity for a novel binding site and chemical selectivity unrelated to local anaesthetic activity. 6. It is proposed that a very high affinity piperazinylindole-selective site is coupled to the phenylalkylamine receptor of Drosophila Ca2(+)-channels. These sites are still present on mammalian L-type Ca2(+)-channels but have lower affinity and/or are less tightly coupled to phenylalkylamine receptors on the alpha 1-subunit.

Full text

PDF
446

Images in this article

449Figure 2
on p.449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armah B. I., Pfeifer T., Ravens U. Reversal of the cardiotonic and action-potential prolonging effects of DPI 201-106 by BDF 8784, a methyl-indol derivative. Br J Pharmacol. 1989 Apr;96(4):807–816. doi: 10.1111/j.1476-5381.1989.tb11888.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boer R., Grassegger A., Schudt C., Glossmann H. (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131–145. doi: 10.1016/0922-4106(89)90004-7. [DOI] [PubMed] [Google Scholar]
  4. DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. doi: 10.1152/ajpendo.1978.235.2.E97. [DOI] [PubMed] [Google Scholar]
  5. Galizzi J. P., Fosset M., Romey G., Laduron P., Lazdunski M. Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7513–7517. doi: 10.1073/pnas.83.19.7513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glossmann H., Ferry D. R. Assay for calcium channels. Methods Enzymol. 1985;109:513–550. doi: 10.1016/0076-6879(85)09112-1. [DOI] [PubMed] [Google Scholar]
  7. Glossmann H., Striessnig J. Molecular properties of calcium channels. Rev Physiol Biochem Pharmacol. 1990;114:1–105. doi: 10.1007/BFb0031018. [DOI] [PubMed] [Google Scholar]
  8. Goll A., Ferry D. R., Striessnig J., Schober M., Glossmann H. (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371–377. doi: 10.1016/0014-5793(84)81199-0. [DOI] [PubMed] [Google Scholar]
  9. Grassegger A., Striessnig J., Weiler M., Knaus H. G., Glossmann H. [3H]HOE166 defines a novel calcium antagonist drug receptor--distinct from the 1,4 dihydropyridine binding domain. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6 Pt 2):752–759. doi: 10.1007/BF00169685. [DOI] [PubMed] [Google Scholar]
  10. Hof R. P., Hof A. Mechanism of the vasodilator effects of the cardiotonic agent DPI 201-106. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1188–1192. doi: 10.1097/00005344-198511000-00028. [DOI] [PubMed] [Google Scholar]
  11. Holck M., Osterrieder W. Interaction of the cardiotonic agent DPI 201-106 with cardiac Ca2+ channels. J Cardiovasc Pharmacol. 1988 Apr;11(4):478–482. doi: 10.1097/00005344-198804000-00015. [DOI] [PubMed] [Google Scholar]
  12. Hosey M. M., Lazdunski M. Calcium channels: molecular pharmacology, structure and regulation. J Membr Biol. 1988 Sep;104(2):81–105. doi: 10.1007/BF01870922. [DOI] [PubMed] [Google Scholar]
  13. King V. F., Garcia M. L., Himmel D., Reuben J. P., Lam Y. K., Pan J. X., Han G. Q., Kaczorowski G. J. Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J Biol Chem. 1988 Feb 15;263(5):2238–2244. [PubMed] [Google Scholar]
  14. Knaus H. G., Scheffauer F., Romanin C., Schindler H. G., Glossmann H. Heparin binds with high affinity to voltage-dependent L-type Ca2+ channels. Evidence for an agonistic action. J Biol Chem. 1990 Jul 5;265(19):11156–11166. [PubMed] [Google Scholar]
  15. Mir A. K., Spedding M. Calcium antagonist properties of diclofurime isomers. II. Molecular aspects: allosteric interactions with dihydropyridine recognition sites. J Cardiovasc Pharmacol. 1987 Apr;9(4):469–477. doi: 10.1097/00005344-198704000-00012. [DOI] [PubMed] [Google Scholar]
  16. Pauron D., Qar J., Barhanin J., Fournier D., Cuany A., Pralavorio M., Berge J. B., Lazdunski M. Identification and affinity labeling of very high affinity binding sites for the phenylalkylamine series of Ca+ channel blockers in the Drosophila nervous system. Biochemistry. 1987 Oct 6;26(20):6311–6315. doi: 10.1021/bi00394a003. [DOI] [PubMed] [Google Scholar]
  17. Pelzer S., Barhanin J., Pauron D., Trautwein W., Lazdunski M., Pelzer D. Diversity and novel pharmacological properties of Ca2+ channels in Drosophila brain membranes. EMBO J. 1989 Aug;8(8):2365–2371. doi: 10.1002/j.1460-2075.1989.tb08365.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Romey G., Quast U., Pauron D., Frelin C., Renaud J. F., Lazdunski M. Na+ channels as sites of action of the cardioactive agent DPI 201-106 with agonist and antagonist enantiomers. Proc Natl Acad Sci U S A. 1987 Feb;84(3):896–900. doi: 10.1073/pnas.84.3.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schmid A., Romey G., Barhanin J., Lazdunski M. SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action. Mol Pharmacol. 1989 Jun;35(6):766–773. [PubMed] [Google Scholar]
  20. Scholtysik G., Salzmann R., Berthold R., Herzig J. W., Quast U., Markstein R. DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties. Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):316–325. doi: 10.1007/BF00501887. [DOI] [PubMed] [Google Scholar]
  21. Siegl P. K., Garcia M. L., King V. F., Scott A. L., Morgan G., Kaczorowski G. J. Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium channels. Naunyn Schmiedebergs Arch Pharmacol. 1988 Dec;338(6):684–691. doi: 10.1007/BF00165635. [DOI] [PubMed] [Google Scholar]
  22. Spedding M. Assessment of "Ca2+ -antagonist" effects of drugs in K+ -depolarized smooth muscle. Differentiation of antagonist subgroups. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):234–240. doi: 10.1007/BF00500485. [DOI] [PubMed] [Google Scholar]
  23. Spedding M., Gittos M., Mir A. K. Calcium antagonist properties of diclofurime isomers. I. Functional aspects. J Cardiovasc Pharmacol. 1987 Apr;9(4):461–468. doi: 10.1097/00005344-198704000-00011. [DOI] [PubMed] [Google Scholar]
  24. Takahashi K., Endoh M., Taira N. Inotropic versus chronotropic, dromotropic, and coronary vasodilator actions of DPI 201-106, a novel positive inotropic agent, in the dog heart. J Cardiovasc Pharmacol. 1987 Apr;9(4):451–460. doi: 10.1097/00005344-198704000-00010. [DOI] [PubMed] [Google Scholar]
  25. Vaghy P. L., Striessnig J., Miwa K., Knaus H. G., Itagaki K., McKenna E., Glossmann H., Schwartz A. Identification of a novel 1,4-dihydropyridine- and phenylalkylamine-binding polypeptide in calcium channel preparations. J Biol Chem. 1987 Oct 15;262(29):14337–14342. [PubMed] [Google Scholar]
  26. Wang G., Dugas M., Ben Armah I., Honerjäger P. Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17–24. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES